Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Frontiers in Immunology

Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions

22 more authors
6 affiliations
  1. 1Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
  2. 2Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
  3. 3Hubei Clinical Cancer Study Center, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
  4. 4Wuhan Binhui Biopharmaceutical Co., Ltd., Wuhan, Hubei, China
  5. 5National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei Provincial Cooperative Innovation Center of Industrial Fermentation, College of Bioengineering, Hubei University of Technology, Wuhan, China
  6. 6Hubei Key Laboratory of Industrial Microbiology, College of Bioengineering, Hubei University of Technology, Wuhan, China

Abstract

Oncolytic viruses (OVs) preferentially infect and replicate within tumors, induce immunogenic cell death, and remodel immune-poor microenvironments to support T-cell infiltration. These features provide a rationale for combining OVs with immune checkpoint blockade, adoptive cellular therapies, bispecific T-cell engagers, cancer vaccines, and innate immune agonists, and for engineering viruses to express immunostimulatory cytokines. Clinical outcomes, however, have been inconsistent. In MASTERKEY-265, adding intratumoral talimogene laherparepvec to pembrolizumab did not significantly improve progression-free or overall survival in advanced melanoma, despite a 62% objective response rate in the preceding 21-patient phase Ib cohort and evidence of increased intratumoral CD8+ T cells and PD-L1 expression. In contrast, single-arm clinical data for RP1 plus nivolumab in anti-PD-1-refractory melanoma showed objective responses, including durable responses in a subset; the U.S. Food and Drug Administration granted accelerated approval for the regimen, but randomized confirmation remains required. Together with the failure of PHOCUS, these findings indicate that benefit is determined by viral platform, tumor immune state, disease and prior-treatment setting, delivery feasibility, and resistance biology rather than immune activation alone. We critically synthesize positive and negative evidence across checkpoint and non-checkpoint strategies and distinguish biomarkers derived from OV studies from those extrapolated from checkpoint-inhibitor trials. Candidate biomarkers and pharmacodynamic readouts are organized into a three-tier research framework covering pretreatment characterization, platform–partner hypotheses, and on-treatment monitoring; their utility for selecting OV-based combinations still requires validation. We further examine delivery barriers, antiviral immunity, tumor heterogeneity and resistance, next-generation vector engineering, and computational approaches to molecularly guided patient selection. Prospective validation in biomarker-stratified, adaptive trials is needed to improve patient selection, match viral platforms with rational partners, and translate biological activity into durable clinical benefit.

Related

  1. Oncolytic reovirus: tumor-microenvironment remodeling, engineering constraints, and translational strategies
    Rui Li, Xiafei Liu, Xiliang Cong +4
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  2. ICAM-1 as a biomarker of efficacy for oncolytic coxsackievirus A21 in patient-derived Ewing sarcoma models
    Richard T. Baugh, Tyler Barr, Elizabeth A. Roundhill +5
    Molecular Therapy OncologyPeer-reviewedCC BY 4.0Full textGenetics & genomicsPMC
  3. Targeting Toll-like Receptors to Enhance Oncolytic Virotherapy: Strategies and Emerging Perspectives
    Siqian Lan, Xiaoqiang Hao, Dongming Zhou +2
    BiomoleculesPeer-reviewedCC BY 4.0Genetics & genomicsCrossref
  4. Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy
    Victor Arias, James H Clubb, Tatiana V Kudling +25
    Journal for Immunotherapy of CancerPeer-reviewedCC BY 4.0Full textGenetics & genomicsPMC
  5. Azospirillum brasilense and cytidine as combination treatment to enhance drought resilience of peas
    B. Ojha, J. Tagoe, S. M. Horne +1
    bioRxivPreprintAll rights reservedFull textMicrobiologybioRxiv
BibTeX
@article{wang2026oncolytic,
  title = {{Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions}},
  author = {Qingqing Wang and Qingqing Wang and Qingqing Wang and Jing Su and Jing Su and Jing Su and Yu Gao and Yu Gao and Yu Gao and Yongge Luo and Yongge Luo and Yongge Luo and Kejie Zhou and Kejie Zhou and Kejie Zhou and Xinyu Huang and Xinyu Huang and Xinyu Huang and Zongchang Yang and Zongchang Yang and Zongchang Yang and Hanming Wang and Lei Yang and Lei Yang and Lei Yang and Han Wu and Han Wu and Han Wu and Binlei Liu and Binlei Liu and Binlei Liu and Fuxiang Zhou and Fuxiang Zhou and Fuxiang Zhou},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = nov,
  doi = {10.3389/fimmu.2026.1986810},
  url = {https://doi.org/10.3389/fimmu.2026.1986810},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Oncolytic viruses in combination cancer therapy: clinical lessons, biomarker-guided strategies, and future treatment directions
AU  - Qingqing Wang
AU  - Qingqing Wang
AU  - Qingqing Wang
AU  - Jing Su
AU  - Jing Su
AU  - Jing Su
AU  - Yu Gao
AU  - Yu Gao
AU  - Yu Gao
AU  - Yongge Luo
AU  - Yongge Luo
AU  - Yongge Luo
AU  - Kejie Zhou
AU  - Kejie Zhou
AU  - Kejie Zhou
AU  - Xinyu Huang
AU  - Xinyu Huang
AU  - Xinyu Huang
AU  - Zongchang Yang
AU  - Zongchang Yang
AU  - Zongchang Yang
AU  - Hanming Wang
AU  - Lei Yang
AU  - Lei Yang
AU  - Lei Yang
AU  - Han Wu
AU  - Han Wu
AU  - Han Wu
AU  - Binlei Liu
AU  - Binlei Liu
AU  - Binlei Liu
AU  - Fuxiang Zhou
AU  - Fuxiang Zhou
AU  - Fuxiang Zhou
PY  - 2026
DA  - 2026/11/11
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1986810
UR  - https://doi.org/10.3389/fimmu.2026.1986810
AB  - Oncolytic viruses (OVs) preferentially infect and replicate within tumors, induce immunogenic cell death, and remodel immune-poor microenvironments to support T-cell infiltration. These features provide a rationale for combining OVs with immune checkpoint blockade, adoptive cellular therapies, bispecific T-cell engagers, cancer vaccines, and innate immune agonists, and for engineering viruses to express immunostimulatory cytokines. Clinical outcomes, however, have been inconsistent. In MASTERKEY-265, adding intratumoral talimogene laherparepvec to pembrolizumab did not significantly improve progression-free or overall survival in advanced melanoma, despite a 62% objective response rate in the preceding 21-patient phase Ib cohort and evidence of increased intratumoral CD8+ T cells and PD-L1 expression. In contrast, single-arm clinical data for RP1 plus nivolumab in anti-PD-1-refractory melanoma showed objective responses, including durable responses in a subset; the U.S. Food and Drug Administration granted accelerated approval for the regimen, but randomized confirmation remains required. Together with the failure of PHOCUS, these findings indicate that benefit is determined by viral platform, tumor immune state, disease and prior-treatment setting, delivery feasibility, and resistance biology rather than immune activation alone. We critically synthesize positive and negative evidence across checkpoint and non-checkpoint strategies and distinguish biomarkers derived from OV studies from those extrapolated from checkpoint-inhibitor trials. Candidate biomarkers and pharmacodynamic readouts are organized into a three-tier research framework covering pretreatment characterization, platform–partner hypotheses, and on-treatment monitoring; their utility for selecting OV-based combinations still requires validation. We further examine delivery barriers, antiviral immunity, tumor heterogeneity and resistance, next-generation vector engineering, and computational approaches to molecularly guided patient selection. Prospective validation in biomarker-stratified, adaptive trials is needed to improve patient selection, match viral platforms with rational partners, and translate biological activity into durable clinical benefit.
SN  - 1664-3224
ER  -